SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
Germline testing is a genetic screening that looks for inherited gene mutations found in every cell.  It can identify ...
Please provide your email address to receive an email when new articles are posted on . Black men with prostate cancer had significantly greater odds of having alterations in immunotherapy targets ...
Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...
Scientist examining genetic testing results on a screen High-grade tumors do not directly evolve from lower-grade ones, but both likely emerge from a common, pre-malignant mutagenic field. A recent ...
Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...
Myriad Genetics, Inc. has announced a strategic collaboration with PATHOMIQ, Inc., which allows Myriad to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer diagnostics ...
Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
Risk factors are things that raise your chances of getting a disease. For each person, there’s a mix of genetic, biological and lifestyle factors that play a part in prostate cancer risk. About 1 in ...
Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But what does it mean for this type of cancer to be called aggressive? As a ...
Scientists at NYU Langone Health examined cancerous and benign tissues from 10 patients with prostate cancer and found “small fragments of plastic” in both — but the tumors had much higher ...